# US 2011/0257156 A1 · Gamma secretase modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257156 A1
- Document ID: US20110257156A1
- Status: Published application
- Kind: A1
- Application number: 13/126,056
- Filed: 2009-11-05
- Published: 2011-10-20
- Earliest claimed: 2008-11-06
- Inventors: Zhaoning Zhu; William J. Greenlee; David James Cole; Dmitri A. Pissarnitski; Gioconda V. Gallo; Hongmei Li; Hubert B. Josien; Jun Qin; Chad E. Knutson; Mihirbaran Mandal; Monica L. Vicarel; Murali Rajagopalan; Pawan Kumar Dhondi; Ruo Xu; Zhong-Yue Sun; Thomas A. Bara; Xianhai Huang; Xiaohong Zhu; Zhiqiang Zhao; John W. Clader; Anandan Palani; Theodros Asberom; Troy McCracken; Chad E. Bennett
- Web page: https://patentgrep.com/patent/US20110257156A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 498/04: Ortho-condensed systems
- C07D 498/20: Spiro-condensed systems
- C07F 7/0812: {comprising a heterocyclic ring}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

In its many embodiments, the present invention provides novel heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A compound selected from the group consisting of: compounds P2, Q3, R2, S3, T2, U2, V8, W6, X2, X3, Y2, Z2, AA2, AA3, AB2, AC12, AD7, AE4, AG2, AH7, AI2, AJ12, 201-214, 216-266, 268-424, 437-465, and 468-553, or a pharmaceutically acceptable salt thereof.

### Claim 17

A compound selected from the group consisting of: compounds P2, Q3, R2, S3, T2, U2, V8, W6, X2, X3, Y2, Z2, AA2, AA3, AB2, AC12, AD7, AE4, AG2, AH7, 201-214, 216-266, 268-424, and 437-446.

### Claim 18 (depends on 16)

A pharmaceutically acceptable salt of a compound of claim 16.

### Claim 19 (depends on 16)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 16 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 16)

A method of modulating gamma-secretase comprising administering an effective amount of one or more compounds of claim 16 or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

### Claim 21 (depends on 16)

A method of inhibiting the deposition of amyloid protein in, on or around neurological tissue, comprising administering an effective amount of one or more compounds of claim 16 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.

### Claim 22 (depends on 16)

A method of treating Alzheimer's disease, comprising administering an effective amount of one or more compounds of claim 16 or a pharmaceutically acceptable salt thereof to a patient in need of treatment.
